Alteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In Subcutaneous ENHERTU Development
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
Alteogen Enters Into An Exclusive License Agreement To Develop And Commercialize Subcutaneous ENHERTU® Enabled By Alteogen's Hybrozymetm Technology
ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...
Le Lézard51m
'From Chancay to Shanghai': A revelation of the times: Global Times editorial
During the 31st APEC Economic Leaders' Meeting in Lima, Peru, this week, a milestone will be reached - the Chancay Port, controlled and invested by Chinese enterprises, is set to hold its operation ...